Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (March 2021)
28 slides from Osteopore's investor presentation, Mar 22, 2021
Slide 1: Investor Presentation March 2021
For personal use only INVESTOR PRESENTATION MARCH 2021 INVESTOR PRESENTATION OSTEOPORE.COM
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not tr
Slide 3: Transformative Bone Regeneration Products
TRANSFORMATIVE BONE REGENERATION PRODUCTS For personal use only BREAKTHROUGH TECHNOLOGY IMPROVES LIVES REVENUE INCREASING Unique 3D printed implants that Extremely low probability of issues Revenue is growing as surgeons facilitate vascularisation to accelerate after surgery compared to bone grafts
Slide 4: Investment Highlights
For personal use only INVESTMENT REGULATORY CLEARANCE SCALABLE BUSINESS MODEL HIGHLIGHTS Osteopore’s products are cleared by High margin products with low manufacturing the US FDA, Australian TGA and some capital intensity provide significant opportunity bear the CE mark of conformity to scale the b
Slide 5: Robust Cash Position to Drive Growth
ROBUST CASH For personal use only POSITION TO DRIVE GROWTH Shares on Issue A 117.2m Total Options on Issue B 13.1m ASX: OSX SHARE PRICE PAST 12 MONTHS Market Cap @ $0.44c C $51.5m $0.80 EV @ $0.44 C $42.5m $0.60 CASH BALANCE D $9.0m FY20 Average Quarterly $0.40 ($388k) Net Operating Cash Used A: Sha
Slide 6: Highly Credentialed Team
HIGHLY CREDENTIALED TEAM For personal use only GOH TEOH BRETT KHOON SWEE SANDERCOCK SENG HIN Non-Exec Chairman CEO Non-Exec Director 30-year career spanning both start-ups Co-founder of Osteopore Current CFO of Resmed (ASX:RMD / NYSE: RMD) and global multinational corporations Prof. Teoh has deep re
Slide 7: Breakthrough Bioresorbable Products for Multiple Applications
BREAKTHROUGH BIORESORBABLE PRODUCTS FOR MULTIPLE APPLICATIONS For personal use only Implant that is used for Implant that is used to fill the covering Burr Holes (holes void following a craniotomy in skull) after neurosurgery (the surgical removal of part of the bone from the skull to expose the bra
Slide 8: How Our Implants Facilitate Bone Growth
BURR HOLE IS DRILLED Patients needing surgical repair for skull fractures usually For personal use only receive a “burr hole” during surgery, which is drilled into the skull to relieve pressure often resulting from hemorrhage HOW OUR IMPLANT DRAWS IN BLOOD IMPLANTS Osteopore’s proprietary 3D printed
Slide 9: Superior Products for Large Global Markets
SUPERIOR PRODUCTS FOR LARGE GLOBAL MARKETS TRADITIONAL PROCEDURES For personal use only BONE GRAFT A surgical procedure where bone US$3.9bn material is harvested from the Bone Graft Substitutes Highly customisable Proven to be patient’s own body and applied to Market by 2025 to biomimic different ef
Slide 10: Improved Patient Outcomes & Lower Healthcare Costs
Osteopore implants do not require any IMPROVED PATIENT OUTCOMES & LOWER For personal use only major changes to current clinical procedures HEALTHCARE COSTS Osteopore products address an unmet clinical need by providing readily adaptable implants and reducing complication rates after surgery Provides
Slide 11: Scalable & Customisable Manufacturing
SCALABLE & For personal use only CUSTOMISABLE MANUFACTURING All Osteopore products are fabricated in-house using proprietary 3D printing technology Rapid design, manufacturing and delivery of implants to anywhere in the world • Expanded manufacturing Unique low cost manufacturing process space by 10
Slide 12: Commercial Strategy That Builds Value
#3 INNOVATE Undertaking a number of early- stage, low-capital intensity For personal use only development projects with large potential upside #2 DIVERSIFY PRODUCT RANGE Osteopore is undertaking a number of development COMMERCIAL #1 ACCELERATE programs to launch new REVENUE GROWTH products and expan
Slide 13: Accelerate Revenue Growth
For personal use only ACCELERATE REVENUE GR WTH INVESTOR PRESENTATION OSTEOPORE.COM 13
Slide 14: 4x Consecutive Quarters of Revenue Growth
For personal use only 4X CONSECUTIVE $500,000 QUARTERS OF $429k REVENUE GROWTH $407k $400,000 $354k $341k $313k $300,000 $279k Revenue providing a solid commercial foundation to build from, with the strategy in place to scale $228k Achieving sales growth (41% cc YOY) despite healthcare $200,000 and
Slide 15: Expanding Distribution Network
EXPANDING REVENUE GROWTH STRATEGY For personal use only DISTRIBUTION Leverage distribution partnerships in the key markets to accelerate revenue growth NETWORK 23 DISTRIBUTION PARTNERS CURRENTLY TARGETING Ensure sales teams and surgeons are educated and supported to drive adoption and sales ~1.1 mil
Slide 16: Scalable Opportunity
SCALABLE For personal use only OPPORTUNITY TOTAL NUMBER OF SURGERY TYPE SURGERIES IN 2020 7 Craniotomy / Craniotomy closure 359,428 Burr hole for hematoma evacuation 302,570 Osteopore has superior off-the-shelf products Craniectomy 89,134 products that can be manufactured at scale Burr hole for shun
Slide 17: Australia & Asia Foundational Markets
For personal use only AUSTRALIA FOUNDATIONAL ASIA & NZ MARKETS Well established and experienced Hired dedicated Business distribution partner network in South Development person in Korea, Vietnam, Singapore and Australia Sydney Australia 2020 constant currency year-on-year Signed Australian & NZ rev
Slide 18: Priority Market Expansion
PRIORITY MARKET EXPANSION For personal use only Europe USA CHINA JAPAN + UK Signed US Distribution Signed Co-operation Identify and engage KOL Signed German-Austrian Agreement with Bioplate agreement with Boao Yiling surgeons interested in Distribution Agreement with MTG Medizintechnik Göhl GmbH Lif
Slide 19: Diversifying Product Range
For personal use only DIVERSIFYING PR DUCT RANGE I N V E S T O R P R E S E N TAT I O N OSTEOPORE.COM 19
Slide 20: Dental
DENTAL For personal use only LIMITED SALES IN SINGAPORE Osteopore has developed an enhanced bioresorbable 3D- printed dental plug which promotes bone growth in the jaw, reducing the likelihood of bone shrinkage after tooth PURSUING TGA & USFDA extraction. 510K CLEARANCE & CE MARK Currently, patients
Slide 21: Orthopaedic
ORTHOPAEDIC For personal use only Osteopore has successfully conducted first in human trials using the Osteopore scaffold in a range of US$2BN PA orthopaedic procedures, where significant lengths of long bones have been damaged or diseased. Sales of orthopaedic alternatives The Osteopore scaffold ha
Slide 22: Innovate
For personal use only INN VATE I N V E S T O R P R E S E N TAT I O N OSTEOPORE.COM 10
Slide 23: Innovate: Other Tissue, Veterinary and Research
REGENERATION OF OTHER TISSUE VETERINARY MARKETS For personal use only Osteopore has successfully completed Osteopore has successfully completed multiple animal trials for knee cartilage animal trials for a number of different surgical regeneration, and the Osteopore scaffold applications which could
Slide 24: 2021 Commercial Priorities
2021 COMMERCIAL PRIORITIES For personal use only ACCELERATE REVENUE GROWTH DIVERSIFICATION INNOVATION Experiment with promising novel compound Leverage cranial and maxillofacial products with Leverage dental product regulatory combinations, including PCL-TCP and PCL-TCP- regulatory approval in signi
Slide 25: Appendix
For personal use only APPENDIX I N V E S T O R P R E S E N TAT I O N OSTEOPORE.COM 25
Slide 26: Global Regulatory Approval
GLOBAL For personal use only REGULATORY APPROVAL Osteopore is working towards necessary regulatory approval to expand sales in additional target jurisdictions including; Brazil China Colombia Egypt Israel Japan Current regulatory clearances Potential Future clearances Jordan UAE UK INVESTOR PRESENTA
Slide 27: Sources
SOURCES For personal use only 1 Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K., & Giannoudis, P. V. (2011). Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury, 42, S3-S15. 2 Younger, E. M., & Chapman, M.
Slide 28: Carl Runde, Chief Financial Officer
For personal use only Carl Runde Chief Financial Officer M +61 400 118 017 E: carl_runde@osteopore.com I N V E S T O R P R E S E N TAT I O N OSTEOPORE.COM 28